Alnylam Pharmaceuticals (NASDAQ: ALNY) recently received a number of ratings updates from brokerages and research firms:

  • 10/2/2017 – Alnylam Pharmaceuticals was upgraded by analysts at Goldman Sachs Group, Inc. (The) from a “neutral” rating to a “buy” rating. They now have a $163.00 price target on the stock, up previously from $62.00.
  • 9/26/2017 – Alnylam Pharmaceuticals had its price target raised by analysts at Jefferies Group LLC from $102.00 to $130.00. They now have a “buy” rating on the stock.
  • 9/25/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $124.00 price target on the stock. They wrote, “We reiterate: Ionis is part of our open pair trade that is long Alnylam and short Ionis.) We believe the positive patisiran safety and efficacy data should be considered positive for other players in the RNAi space, including Buy-rated Arbutus Biopharma, which will receive royalties on potential sales of patisiran.””
  • 9/22/2017 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $134.00 price target on the stock, up previously from $99.00.
  • 9/21/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $135.00 price target on the stock, up previously from $94.00.
  • 9/21/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Ladenburg Thalmann Financial Services. They now have a $146.00 price target on the stock, up previously from $90.00.
  • 9/20/2017 – Alnylam Pharmaceuticals had its price target raised by analysts at JMP Securities from $101.00 to $128.00. They now have an “outperform” rating on the stock.
  • 9/20/2017 – Alnylam Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $85.00 to $125.00. They now have a “buy” rating on the stock.
  • 9/20/2017 – Alnylam Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $116.00 price target on the stock, up previously from $110.00.
  • 9/20/2017 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $117.00 price target on the stock, up previously from $93.00.
  • 9/20/2017 – Alnylam Pharmaceuticals had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $83.00 price target on the stock, up previously from $56.00.
  • 9/18/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $102.00 price target on the stock.
  • 9/15/2017 – Alnylam Pharmaceuticals is now covered by analysts at Instinet. They set a “reduce” rating and a $56.00 price target on the stock.
  • 9/14/2017 – Alnylam Pharmaceuticals is now covered by analysts at Nomura. They set a “reduce” rating and a $56.00 price target on the stock.
  • 9/11/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital.
  • 9/8/2017 – Alnylam Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $72.00 price target on the stock, down previously from $83.00. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 9/7/2017 – Alnylam Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $105.00 price target on the stock, up previously from $80.00.
  • 9/7/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock, down previously from $98.00. They wrote, “Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration.””
  • 9/7/2017 – Alnylam Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $110.00 price target on the stock, down previously from $126.00.
  • 9/6/2017 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $99.00 price target on the stock, down previously from $105.00.
  • 9/1/2017 – Alnylam Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/25/2017 – Alnylam Pharmaceuticals was given a new $102.00 price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 8/16/2017 – Alnylam Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 8/11/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Credit Suisse Group. They now have a $96.00 price target on the stock.
  • 8/10/2017 – Alnylam Pharmaceuticals had its price target raised by analysts at Barclays PLC from $50.00 to $70.00. They now have an “equal weight” rating on the stock.
  • 8/10/2017 – Alnylam Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $46.00 to $50.00. They now have an “equal weight” rating on the stock.
  • 8/10/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $124.00 price target on the stock, down previously from $131.00. They wrote, “We believe far and away the least likely scenario is that patisiran fails to demonstrate efficacy in APOLLO, considering that, as discussed above, the clinical effect of TTR silencing has been de- risked by top-line results from NEURO-TTR. A significant disconnect between the APOLLO and NEURO-TTR studies is, in our view, only possible if, as discussed in the 9 January 2017 company note, the differences in the patient population between the phase II OLE and APOLLO study (APOLLO has more advanced patients than the phase II OLE) leads to a slower rate of mNIS+7 increase in the placebo arm than is expected in natural history since, to our understanding, the NEURO-TTR patient population is likely somewhere between the phase II OLE and APOLLO populations.””
  • 8/10/2017 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $56.00 price target on the stock, up previously from $47.00.
  • 8/5/2017 – Alnylam Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 119.90 on Wednesday. The stock has a 50 day moving average price of $91.25 and a 200 day moving average price of $73.76. Alnylam Pharmaceuticals, Inc. has a one year low of $31.38 and a one year high of $125.96. The company’s market capitalization is $11.00 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company had revenue of $15.93 million during the quarter, compared to analyst estimates of $23.86 million. During the same quarter last year, the business earned ($1.05) EPS. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.20) earnings per share for the current year.

In related news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the sale, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.30% of the company’s stock.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings for Alnylam Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.